Boehringer Bemoans Medicare Drug Price Talks As 'A Sham'

By Theresa Schliep · September 28, 2023, 7:38 PM EDT

Boehringer Ingelheim Pharmaceuticals Inc. slammed the new Medicare drug price negotiation program in a Connecticut federal court filing as a "sham from beginning to end," even as it indicated Thursday that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services et al

Case Number

3:23-cv-01103

Court

Connecticut

Nature of Suit

Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision

Date Filed

August 18, 2023

Recent Articles By Theresa

November 19, 2024
Nonpracticing Doc Can't Testify In Med Mal Case, Court Says
November 15, 2024
Despite Vaccine Spotlight, RFK Jr. A Health Policy 'Unknown'
November 14, 2024
Trump Picks RFK Jr. To Lead Health & Human Services
November 12, 2024
Why The CDC May Look Very Different In Trump's 2nd Term
November 05, 2024
Abortion Ballot Tracker: 7 States Add Protections As Fla. Effort Fails
October 29, 2024
Fla. Health Agency's All-Out Battle Against Abortion Measure
October 24, 2024
'Will Of The People' Upheld With Ohio Abortion Ban Quashed
October 22, 2024
A Tenn. Court Gets Specific On Abortion Ban Exceptions
October 08, 2024
New Research Misconduct Rule May Expose, Chill Witnesses
October 07, 2024
High Court Won't Look At Alabama Frozen Embryo Decision